

Giuseppe Floris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8325955/publications.pdf>

Version: 2024-02-01

158
papers

7,756
citations

109264

35
h-index

56687

83
g-index

165
all docs

165
docs citations

165
times ranked

12974
citing authors

#	ARTICLE	IF	CITATIONS
1	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
2	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	2.4	530
3	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immuno-oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
4	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. <i>Cell Research</i> , 2020, 30, 745-762.	5.7	391
5	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021, 27, 820-832.	15.2	330
6	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	9.4	256
7	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	2.9	230
8	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201
9	Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14333-14338.	3.3	194
10	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
11	Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. <i>Cell Metabolism</i> , 2019, 30, 917-936.e10.	7.2	150
12	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
13	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
14	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	3.0	99
15	Update on triple-negative breast cancer: prognosis and management strategies. <i>International Journal of Women's Health</i> , 2012, 4, 511.	1.1	91
16	Cancer and Aging: Two Tightly Interconnected Biological Processes. <i>Cancers</i> , 2021, 13, 1400.	1.7	83
17	Coactivated Platelet-Derived Growth Factor Receptor α and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. <i>Cancer Research</i> , 2010, 70, 7304-7314.	0.4	80
18	Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. <i>Journal of Pathology</i> , 2011, 223, 593-603.	2.1	71

#	ARTICLE	IF	CITATIONS
19	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. <i>Clinical Cancer Research</i> , 2013, 19, 620-630.	3.2	64
20	Depleted Uranium and Human Health. <i>Current Medicinal Chemistry</i> , 2018, 25, 49-64.	1.2	61
21	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911.	2.6	59
22	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 4066-4076.	3.2	53
23	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	2.3	51
24	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrointestinal Stromal Tumor Xenografts Carrying Heterogeneous <i>KIT</i> Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 5604-5614.	3.2	48
25	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. <i>Annals of Oncology</i> , 2012, 23, 2578-2584.	0.6	46
26	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. <i>Clinical Cancer Research</i> , 2014, 20, 6071-6082.	3.2	45
27	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	2.9	45
28	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1897-1908.	1.9	43
29	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22.	2.2	43
30	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. <i>EClinicalMedicine</i> , 2021, 35, 100856.	3.2	42
31	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 867-871.	3.0	41
32	IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis. <i>PLoS ONE</i> , 2011, 6, e19846.	1.1	41
33	A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. <i>Annals of Oncology</i> , 2013, 24, 47-53.	0.6	40
34	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	1.4	40
35	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	2.6	37
36	Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 1-9.	1.1	37

#	ARTICLE	IF	CITATIONS
37	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	0.6	37
38	Frequent activation of EGFR in advanced chordomas. <i>Clinical Sarcoma Research</i> , 2011, 1, 4.	2.3	36
39	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. <i>Cancers</i> , 2021, 13, 3695.	1.7	35
40	Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers. <i>Annals of Oncology</i> , 2013, 24, 1847-1852.	0.6	34
41	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. <i>International Journal of Cancer</i> , 2015, 136, E685-96.	2.3	34
42	Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. <i>Histopathology</i> , 2020, 77, 79-91.	1.6	33
43	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014, 23, 1934-1946.	1.4	32
44	Behavior of metastatic breast cancer according to subtype. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 115-125.	1.1	32
45	Invasive lobular carcinoma with extracellular mucin production—a novel pattern of lobular carcinomas of the breast. <i>Clinico-pathological description of eight cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 3-12.	1.4	31
46	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 146-153.	3.0	31
47	Epithelioid Hemangioma of Bone: A Potentially Metastasizing Tumor?. <i>International Journal of Surgical Pathology</i> , 2006, 14, 9-15.	0.4	30
48	Gold Nanoparticles: A New Golden Era in Oncology?. <i>Pharmaceuticals</i> , 2020, 13, 192.	1.7	30
49	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. <i>British Journal of Cancer</i> , 2022, 127, 988-1013.	2.9	30
50	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor-Positive, Lower Grade Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2222-2231.	1.1	27
51	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2014, 27, 1510-1520.	2.9	27
52	Production of antibodies against the coenzyme pyrroloquinoline quinone. <i>FEBS Letters</i> , 1989, 247, 201-204.	1.3	25
53	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020, 33, 354-366.	2.9	25
54	Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. <i>Clinical Sarcoma Research</i> , 2014, 4, 10.	2.3	24

#	ARTICLE	IF	CITATIONS
55	Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. <i>Acta Clinica Belgica</i> , 2016, 71, 383-388.	0.5	24
56	Age-related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1184.	1.7	24
57	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	1.9	23
58	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. <i>European Journal of Cancer</i> , 2017, 75, 33-40.	1.3	22
59	The footprint of the ageing stroma in older patients with breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 78.	2.2	22
60	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 699-708.	1.1	22
61	Papillary lesions of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 65-84.	1.4	22
62	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. <i>British Journal of Cancer</i> , 2014, 110, 1088-1100.	2.9	21
63	Dichotomous histopathological assessment of ductal carcinoma <i>in situ</i> of the breast results in substantial interobserver concordance. <i>Histopathology</i> , 2018, 73, 923-932.	1.6	21
64	The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. <i>Cancer Research</i> , 2021, 81, 3876-3889.	0.4	21
65	Malignant Ectomesenchymoma: Genetic Profile Reflects Rhabdomyosarcomatous Differentiation. <i>Diagnostic Molecular Pathology</i> , 2007, 16, 243-248.	2.1	19
66	Interobserver agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 191-205.	1.3	19
67	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. <i>Scientific Reports</i> , 2021, 11, 3176.	1.6	17
68	Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies. <i>Cancer Investigation</i> , 2010, 28, 839-848.	0.6	16
69	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 759-770.	1.1	16
70	Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. <i>Breast</i> , 2014, 23, 453-459.	0.9	15
71	Fibromatosis-like metaplastic carcinoma: a case report and review of the literature. <i>Diagnostic Pathology</i> , 2020, 15, 20.	0.9	15
72	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15

#	ARTICLE	IF	CITATIONS
73	Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. <i>Journal of Pathology</i> , 2012, 228, 565-574.	2.1	14
74	Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. <i>Translational Oncology</i> , 2015, 8, 112-118.	1.7	14
75	Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. <i>European Journal of Surgical Oncology</i> , 2019, 45, 550-559.	0.5	14
76	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021, 34, 2130-2140.	2.9	14
77	Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 183-194.	1.1	14
78	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	0.8	14
79	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	1.4	12
80	Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer. <i>SpringerPlus</i> , 2013, 2, 480.	1.2	11
81	Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 473-481.	1.4	11
82	Prognostic implications of lobular breast cancer histology: New insights from a single hospital cross-sectional study and SEER data. <i>Breast</i> , 2014, 23, 371-377.	0.9	10
83	A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer. <i>Breast</i> , 2018, 37, 52-55.	0.9	10
84	Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer. <i>BMC Cancer</i> , 2018, 18, 994.	1.1	9
85	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. <i>Clinical Chemistry</i> , 2020, 66, 1414-1423.	1.5	9
86	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 985-998.	1.1	9
87	Circulating CCL5 Levels in Patients with Breast Cancer: Is There a Correlation with Lymph Node Metastasis?. <i>ISRN Immunology</i> , 2013, 2013, 1-5.	0.7	8
88	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4410.	1.7	8
89	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021, 13, 4910.	1.7	8
90	The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. <i>Breast</i> , 2013, 22, 254-262.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 189-196.	1.1	7
92	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , 2021, 155, 13-24.	1.3	7
93	Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 603-607.	1.1	6
94	Breast cancer subtype and survival by parity and time since last birth. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 481-487.	1.1	6
95	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	1.7	6
96	Granulomatosis with polyangiitis with breast involvement mimicking metastatic cancer: Case report and literature review. <i>European Journal of Rheumatology</i> , 2020, 7, 41-43.	1.3	6
97	A metabolic approach to the treatment of dilated cardiomyopathy in BIO T0â€² cardiomyopathic Syrian hamsters. <i>BioFactors</i> , 2005, 25, 127-135.	2.6	5
98	The Baaderâ€²Meinhof phenomenon in ductal carcinoma <i>in situ</i> of the breast. <i>Histopathology</i> , 2016, 69, 522-523.	1.6	5
99	Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?. <i>Annals of Oncology</i> , 2017, 28, 2317.	0.6	5
100	Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. <i>Journal of Geriatric Oncology</i> , 2018, 9, 606-612.	0.5	5
101	Digital analysis of distant and cancer-associated mammary adipocytes. <i>Breast</i> , 2020, 54, 179-186.	0.9	5
102	Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration. <i>International Journal of Medical Sciences</i> , 2020, 17, 2269-2275.	1.1	5
103	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5
104	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2â€² early breast cancer. <i>Modern Pathology</i> , 2021, 34, 1297-1309.	2.9	5
105	Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. <i>Clinical Drug Investigation</i> , 2018, 38, 1071-1075.	1.1	4
106	Withdrawal of hormone replacement therapy might affect multigene signature results in early luminal breast cancer. <i>Annals of Oncology</i> , 2015, 26, 437-438.	0.6	3
107	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 55-63.	1.1	3
108	Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12558-e12558.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Activity of GDC-0941, an inhibitor of phosphoinositol 3 kinase (PI3K), in gastrointestinal stromal tumor (GIST) xenograft and duration of response after discontinuation of treatment in combination with imatinib.. Journal of Clinical Oncology, 2010, 28, 10020-10020.	0.8	3
110	Assessment of the heat shock protein 90 (HSP90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of human gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology, 2009, 27, 10534-10534.	0.8	3
111	Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer. Cancers, 2021, 13, 2185.	1.7	2
112	Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. Npj Breast Cancer, 2021, 7, 128.	2.3	2
113	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. Data in Brief, 2021, 38, 107354.	0.5	2
114	Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models.. Journal of Clinical Oncology, 2012, 30, 10030-10030.	0.8	2
115	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. Journal of Clinical Oncology, 2013, 31, 10573-10573.	0.8	2
116	NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2018, 36, 12010-12010.	0.8	2
117	Indications and limits of palliative resection for gastric cancer: our experience. Journal of Chemotherapy, 1999, 11, 224-226.	0.7	1
118	Is the sentinel lymph node biopsy more sensitive for the identification of positive lymph nodes in breast cancer than the axillary lymph node dissection?. SpringerPlus, 2013, 2, 275.	1.2	1
119	Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling. Annals of Oncology, 2019, 30, iii45.	0.6	1
120	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1041-1048.	1.2	1
121	Abstract P5-09-05: Hereditary breast cancer beyond BRCA: Clinical and histopathological characteristics in patients with germline CHEK2, ATM, PALB2 and TP53-mutations. , 2019, , .		1
122	Abstract P5-06-28: Optimization and validation ofPIK3CAmutation detection with droplet digital PCR in liquid biopsies of patients with metastatic breast cancer. , 2020, , .		1
123	Sentinel Lymph Node Involvement in Ductal Carcinoma In-Situ of the Breast: Two Different Causes. Clinical Breast Cancer, 2012, 12, 378-381.	1.1	0
124	A Negative Progesterone Receptor in Luminal Her-2 Negative Breast Cancer by Age at Diagnosis: 10 Years Follow-Up. Annals of Oncology, 2014, 25, i8.	0.6	0
125	P270 Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab. Breast, 2015, 24, S119.	0.9	0
126	Inter-rater reliability in the assessment of stromal characteristics in ductal carcinoma in situ of the breast: how consistent are we?. Breast, 2017, 32, S48-S49.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Treatment decision in early stage ER+ HER2 ⁺ breast cancer without the 70-gene signature test: a retrospective analysis. <i>Breast</i> , 2017, 32, S130-S131.	0.9	0
128	Evaluation of the concordance of immunological biomarkers between core biopsy and corresponding resection specimen in ER/PR negative breast cancer. <i>European Journal of Cancer</i> , 2018, 92, S134.	1.3	0
129	Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty. <i>Annals of Oncology</i> , 2019, 30, xi49.	0.6	0
130	DETAILED ANALYSIS OF TUMOR INFILTRATING LYMPHOCYTES IN THREE AGE CATEGORIES OF BREAST CANCER PATIENTS: CORRELATION WITH SYSTEMIC IMMUNOSENESCENCE/FRAILTY MARKERS. <i>Journal of Geriatric Oncology</i> , 2019, 10, S120-S121.	0.5	0
131	67P Digital analysis of distant and cancer-associated adipocytes in breast cancer. <i>Annals of Oncology</i> , 2020, 31, S37-S38.	0.6	0
132	Tyrosine kinases as possible therapeutic targets in pulmonary artery intimal sarcoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 10055-10055.	0.8	0
133	Efficacy of the phosphoinositol 3 kinase (PI3K) inhibitor GDC-0941 in patient- and cell-line-derived xenografts of dedifferentiated liposarcoma (DDLPS).. <i>Journal of Clinical Oncology</i> , 2013, 31, e13528-e13528.	0.8	0
134	Abstract P6-08-05: Prognostic value of the progesterone receptor by proliferation rate in patients with luminal HER2 negative breast cancer. , 2015, , .		0
135	Abstract P6-08-02: The body mass index interacts with the prognostic effect of the progesterone receptor in patients with a luminal HER2 negative breast cancer. , 2015, , .		0
136	Abstract 1461: A panel of patient derived gastrointestinal stromal tumors (GIST) xenograft models for in vivo preclinical drug testing. , 2015, , .		0
137	Abstract P5-08-31: Withdrawal of exogenous hormones affects prognostic multigene signature results in early luminal breast cancer. , 2016, , .		0
138	Abstract 5197: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS): a preclinical platform for early drug testing. , 2016, , .		0
139	Abstract P2-03-05: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients. , 2017, , .		0
140	Abstract P3-03-32: Monocentric experience with the sentinel lymph node biopsy prior to neoadjuvant chemotherapy in clinically lymph node negative early breast cancer. , 2019, , .		0
141	The prognostic role of the androgen receptor in patients with triple-negative early breast cancers and primary surgery.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12042-e12042.	0.8	0
142	Abstract 1406: Multigene signatures based risk estimates in ER+/HER2- breast cancers: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use. , 2019, , .		0
143	Abstract P5-02-04: Upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast to reduce inter-observer variability: The DCISion study. , 2020, , .		0
144	Abstract P3-07-14: Multigene signatures based risk estimates in early ER+/HER2- breast cancer: The predictive value of inexpensive statistical models and changes in adjuvant chemotherapy use. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
145	Abstract P1-10-04: Impact of body mass index (BMI) on the predictive and prognostic value of stromal tumor-infiltrating lymphocytes (sTIL) in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NACT). , 2020, , .		0
146	Abstract P6-10-13: Associated ductal carcinoma in situ in primary operated TNBC is associated with a longer time to distant event. , 2020, , .		0
147	Abstract P3-08-26: Clinico-pathological characteristics of metaplastic breast cancer as compared to normal TNBC: A single center analysis. , 2020, , .		0
148	Abstract P5-06-08: Predicting distant recurrence of ER+ HER2- breast cancer after 5 years of endocrine therapy: The CTS5-tool validation in real life. , 2020, , .		0
149	Abstract P5-04-23: Characterization of the tumor microenvironment in a large series of ER/PR negative breast cancer. , 2020, , .		0
150	Abstract P3-08-31: Clinical and pathological features of invasive micropapillary carcinoma of the breast and correlation with prognosis. , 2020, , .		0
151	Abstract P6-08-03: Germline mutational landscape in 5422 individuals at risk for hereditary breast and ovarian cancer who underwent multi-gene panel testing. , 2020, , .		0
152	Abstract P1-10-07: The presence of ductal carcinoma in situ in core needle biopsy and microcalcifications on mammography in TNBC is associated with a lower pCR and worse long term outcome. , 2020, , .		0
153	Abstract P2-14-23: Outcome of patients with triple-negative breast cancer who did not receive adjuvant chemotherapy. , 2020, , .		0
154	A rare case of vagus nerve schwannoma. <i>Chirurgia Italiana</i> , 2007, 59, 907-10.	0.2	0
155	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). <i>Cancer Research</i> , 2022, 82, P1-02-09-P1-02-09.	0.4	0
156	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-18-P3-09-18.	0.4	0
157	Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. <i>Cancer Research</i> , 2022, 82, P4-02-02-P4-02-02.	0.4	0
158	Abstract P3-08-07: Comparison of the genomic alterations in metastatic inflammatory and non-inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P3-08-07-P3-08-07.	0.4	0